Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra in Japanese Patients With Still's Disease
NCT05814159Phase 3Active, not recruiting
- Sponsor
- Sobi
- Start
- Aug 2022
- Primary completion
- Dec 2025
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic juvenile idiopathic arthritis (SJIA) and adult-onset Still's disease (AOSD) comparing Anakinra Arm with Placebo Arm (2 arms). Primary endpoints: Physician Global Assessment of Disease Activity at 2 weeks, Patient/Parent Global Assessment of Overall Well-being at 2 weeks and 4 more. Started Aug 2022; status: active, not recruiting.
02
Drugs
anakinra
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)adult-onset Still's disease (AOSD)
Beyond the preview
Go deeper on NCT05814159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05814159.